🇺🇸 FDA
Pipeline program

PACLITAXEL, GEMCITABINE HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, GEMCITABINE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, IMFINZI 50 mg/mL concentrate for solution for infusion.

D9106C00001

Phase 3 small_molecule active

Quick answer

PACLITAXEL, GEMCITABINE HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, GEMCITABINE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, IMFINZI 50 mg/mL concentrate for solution for infusion. for Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB; either squamous or non-squamous). is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB; either squamous or non-squamous).
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials